Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.

Isabelle Kone-PautStéphanie TellierAlexandre BelotKarine BrochardCorinne GuittonIsabelle MarieUlrich MeinzerBilade CherqaouiCaroline GaleottiNadja BoukhedouniHelene AgostiniMoshe ArditiVirginie LambertCéline Piedvache

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2020)

Anakinra was well tolerated in the study patients and may have some efficacy in reducing fever, markers of systemic inflammation, and coronary artery dilatation in individuals with IVIG-refractory KD.

Keyphrases

phase ii
open label
coronary artery
clinical trial
ejection fraction
newly diagnosed
squamous cell carcinoma
randomized controlled trial
pulmonary artery
study protocol
pulmonary hypertension
patient reported outcomes
placebo controlled
locally advanced